Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.

Company Overview and News

OCBC's Bank of Singapore picks Luxembourg for Europe hub

2018-07-16 theedgemarkets
BENGALURU (July 16): Bank of Singapore, the private banking division of Singapore's second-largest listed lender Oversea-Chinese Banking Corp, has set up a wealth management subsidiary in Luxembourg so it can serve European customers, Luxembourg for Finance said.
O39 0165

MedTech Overcomes Policy Hurdles, Long-Term Prospects Bright

2018-06-16 zacks
With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism. AdvaMed, the medical device industry’s lobbying group, which strongly advocated for this relief, noted that the tax repeal will provide a huge impetus to the companies to channelize their turnovers into strategic consolidations, research and developments and also help in creating new job opportunities.

A day of reckoning may be coming for China's bond market

2018-05-25 cnbc
It's a mixed bag – a green energy developer, a shoemaker, a telecom equipment manufacturer and a port on the border with North Korea.

Is the day of reckoning coming for China’s corporate bond market?

2018-05-25 scmp
A flurry of defaults is raising expectations that there could be many more to come as Beijing clamps down on financial risk

Ant Financial to help state lender China Everbright Bank develop fintech capabilities

2018-05-23 scmp
Ant Financial, an affiliate of Chinese e-commerce giant Alibaba Group Holding, said on Wednesday it had signed a strategic cooperation agreement with China Everbright Bank and its financial technology affiliate Everbright Technology, to help the state bank with its digital transformation.
BABA 0700 0165

Tencent eyes big picture as it forms partnership with Tang Media and China Everbright

2018-04-09 scmp
The Chinese internet giant’s arms – Tencent Pictures and Tencent Penguin Pictures – join hands with Tang Media and China Everbright to distribute films and produce original television content for Chinese audiences
BABA 0700 0165

Five Things You Need to Know to Start Your Day - Bloomberg

2018-03-27 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

US virtual currency trading platform Circle plans big expansion in Asia

2018-03-16 scmp
The platform, backed by IDG Capital, Goldman Sachs and Baidu, will focus on helping Asia institutions trade digital tokens

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

14h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

15h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...